Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

The invention relates to compositions and uses thereof in methods for treating an inflammatory disease, disorder or condition in a subject, in particular an inflammatory disease, disorder or condition of the digestive tract such as inflammatory bowel disease (IBD) and/or colorectal cancer. The invention also relates to probiotic compositions and the use of the compositions for treating gastrointestinal disorders.

The invention relates to compositions and uses thereof in methods for treating an inflammatory disease, disorder or condition in a subject, in particular an inflammatory disease, disorder or condition of the digestive tract such as inflammatory bowel disease (IBD) and/or colorectal cancer. The invention also relates to probiotic compositions and the use of the compositions for treating gastrointestinal disorders.

In various embodiments methods of preparing hydroxybutyryl 3-hydroxybutyrate and related compounds are provided along with methods of use thereof.

In various embodiments methods of preparing hydroxybutyryl 3-hydroxybutyrate and related compounds are provided along with methods of use thereof.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.

The present disclosure relates to a Clostridium sp. JS66 strain producing metabolites having 4 to 6 carbon atoms in a high yield. The strain produces metabolites having 6 carbon atoms in a significantly high yield while reducing the production of acetic acid and ethanol as by-products.

The present disclosure relates to a Clostridium sp. JS66 strain producing metabolites having 4 to 6 carbon atoms in a high yield. The strain produces metabolites having 6 carbon atoms in a significantly high yield while reducing the production of acetic acid and ethanol as by-products.

Process for the production of an organic acid from a lignocellulosic feedstock. The process is integrated with a pulp mill and comprises: a) pre-treating a lignocellulosic feedstock with an alkaline liquor from the pulp, thereby obtaining a pretreated cellulosic feed and a black liquor; b) subjecting the pretreated cellulosic feed from step a) to enzymatic hydrolysis, thereby obtaining a saccharide feed; c) subjecting the saccharide feed from step b) to microbial fermentation using calcium oxide from the pulp mill as a neutralising agent, thereby obtaining an organic acid calcium salt; d) treating the organic acid calcium salt with sulfuric acid, thereby obtaining the organic acid; e) optionally isolating lignin from the black liquor obtained in step a), thereby obtaining lignin and weak black liquor; and f) returning the black liquor from step a) and/or the weak black liquor from step e) to the pulp mill chemical recovery process.

Process for the production of an organic acid from a lignocellulosic feedstock. The process is integrated with a pulp mill and comprises: a) pre-treating a lignocellulosic feedstock with an alkaline liquor from the pulp, thereby obtaining a pretreated cellulosic feed and a black liquor; b) subjecting the pretreated cellulosic feed from step a) to enzymatic hydrolysis, thereby obtaining a saccharide feed; c) subjecting the saccharide feed from step b) to microbial fermentation using calcium oxide from the pulp mill as a neutralising agent, thereby obtaining an organic acid calcium salt; d) treating the organic acid calcium salt with sulfuric acid, thereby obtaining the organic acid; e) optionally isolating lignin from the black liquor obtained in step a), thereby obtaining lignin and weak black liquor; and f) returning the black liquor from step a) and/or the weak black liquor from step e) to the pulp mill chemical recovery process.